المؤلفون: Hendrik P. Verschuur, Rudolf G. J. Wiggenraad, Frank J. F. Jeurissen, Lucia B. Vrolijk, Marije Slingerland, Camiel L.M. de Roij van Zuijdewijn

المساهمون: Nephrology, ACS - Diabetes & metabolism

المصدر: Clinical otolaryngology, 44(2), 172-175. Wiley-Blackwell
Clinical Otolaryngology, 44(2), 172-175. WILEY

مصطلحات موضوعية: Male, medicine.medical_specialty, Cetuximab, Antineoplastic Agents, Antineoplastic Agents, Immunological, Enteral Nutrition, Antineoplastic Agents, Immunological/administration & dosage, Immunological/administration & dosage, PEG ratio, medicine, Humans, Aged, Cetuximab/administration & dosage, Retrospective Studies, Gastrostomy, Tube dependency, business.industry, Head and neck cancer, Head and Neck Neoplasms/drug therapy, Retrospective cohort study, Chemoradiotherapy, Gastrostomy/adverse effects, Middle Aged, medicine.disease, Enteral Nutrition/adverse effects, Otorhinolaryngology, Head and Neck Neoplasms, Female, Radiology, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2d9196d8e60138d57b1080b63d7da2eTest
https://doi.org/10.1111/coa.13282Test

المؤلفون: Davide Rossi, Rahel Schwotzer, Raphael Heimgartner, Andreas J. Flammer, Georg Stussi, Bernhard Gerber, Guido Ghilardi, Erika Lerch, Christine Waibel, Harald Seeger, Clemens Caspar, Stefanie Pederiva, Thomas Fehr, Elena Bianchi, Markus G. Manz, Sofie Brouwers

المساهمون: Pharmaceutical and Pharmacological Sciences, Clinical Pharmacology and Clinical Pharmacy, Experimental Pharmacology, University of Zurich, Schwotzer, Rahel

المصدر: Hematological Oncology. 37:595-600

مصطلحات موضوعية: Male, Cancer Research, 2720 Hematology, Immunoglobulin Light-chain Amyloidosis/diagnosis, Severity of Illness Index, Gastroenterology, Antineoplastic Agents, Immunological, 0302 clinical medicine, Bone Marrow, Recurrence, Immunoglobulin Light-chain Amyloidosis, 10035 Clinic for Nephrology, 1306 Cancer Research, Bortezomib, Amyloidosis, Antibodies, Monoclonal, Hematology, General Medicine, Middle Aged, Treatment Outcome, medicine.anatomical_structure, Oncology, 030220 oncology & carcinogenesis, Retreatment, 10209 Clinic for Cardiology, 2730 Oncology, Female, medicine.drug, Adult, medicine.medical_specialty, Plasma Cells, Infections/etiology, 610 Medicine & health, Infections, Antibodies, Monoclonal/administration & dosage, 03 medical and health sciences, Antineoplastic Agents, Immunological/administration & dosage, Refractory, Internal medicine, medicine, AL amyloidosis, Humans, Lymphocyte Count, Adverse effect, Aged, Lenalidomide, Bone Marrow/metabolism, business.industry, Daratumumab, medicine.disease, Drug Resistance, Neoplasm, 10032 Clinic for Oncology and Hematology, Plasma Cells/pathology, Bone marrow, business, 030215 immunology

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afce2e4f761edbd1d13b6d39b85360dfTest
https://doi.org/10.1002/hon.2677Test

المؤلفون: Yang Meng, Neil Roskell, Andrew Walker, Helen Johnson, D. Lee, John Ellis, Zoe Philips, N. Hertel, E. Morais

المصدر: Meng, Y, Hertel, N, Ellis, J, Morais, E, Johnson, H, Philips, Z, Roskell, N, Walker, A & Lee, D 2018, ' The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England ', The European Journal of Health Economics, vol. 19, no. 8, pp. 1163-1172 . https://doi.org/10.1007/s10198-018-0964-4Test

مصطلحات موضوعية: Male, Oncology, Skin Neoplasms, Cost effectiveness, Cost-Benefit Analysis, Economics, Econometrics and Finance (miscellaneous), Kaplan-Meier Estimate, Antineoplastic Agents, Immunological, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Oximes, Skin Neoplasms/drug therapy, Melanoma/drug therapy, 030212 general & internal medicine, Vemurafenib, Melanoma, Health Policy, Imidazoles, Age Factors, Ipilimumab/economics, Middle Aged, Markov Chains, Nivolumab/administration & dosage, Dacarbazine, Nivolumab, Models, Economic, Health Resources/economics, 030220 oncology & carcinogenesis, Disease Progression, Health Resources, Female, Quality-Adjusted Life Years, medicine.drug, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Imidazoles/economics, Ipilimumab, Disease-Free Survival, 03 medical and health sciences, Sex Factors, Antineoplastic Agents, Immunological/administration & dosage, Internal medicine, Proto-Oncogene Proteins B-raf/genetics, medicine, Humans, Oximes/economics, Survival analysis, Aged, business.industry, Vemurafenib/economics, Dacarbazine/economics, Dabrafenib, Clinical trial, Health Expenditures, business, Antineoplastic Combined Chemotherapy Protocols/economics

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fbba7ec0a8309e03b0b8e6ffb8f01a95Test
https://doi.org/10.1007/s10198-018-0964-4Test

المؤلفون: Vincent Pillonel, Olivier Michielin, Andreas F. Hottinger, Luis Schiappacasse, Veronica Aedo-Lopez, Gregoire Berthod, Vincent Dunet, Solange Peters

المصدر: Journal for Immunotherapy of Cancer
Journal for immunotherapy of cancer, vol. 7, no. 1, pp. 336
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-6 (2019)

مصطلحات موضوعية: 0301 basic medicine, Oncology, Adult, Male, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, CNS demyelination, Immunology, Remission, Spontaneous, Spontaneous remission, Case Report, Metastatic melanoma, lcsh:RC254-282, Asymptomatic, 03 medical and health sciences, Immune checkpoint inhibitors, 0302 clinical medicine, Antineoplastic Agents, Immunological, Immune related adverse events, Internal medicine, medicine, Image Processing, Computer-Assisted, Immunology and Allergy, Humans, Antineoplastic Agents, Immunological/administration & dosage, Antineoplastic Agents, Immunological/adverse effects, Asymptomatic Diseases, Demyelinating Diseases/diagnosis, Demyelinating Diseases/etiology, Magnetic Resonance Imaging, Melanoma/complications, Melanoma/diagnosis, Melanoma/drug therapy, Nivolumab/administration & dosage, Nivolumab/adverse effects, Neurological toxicities, Nivolumab, Melanoma, Pharmacology, business.industry, Immunotherapy, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, Hyperintensity, 030104 developmental biology, 030220 oncology & carcinogenesis, Molecular Medicine, medicine.symptom, business, Demyelinating Diseases

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::405a051ce719beb9bfa688acb52fdc90Test
https://pubmed.ncbi.nlm.nih.gov/31791418Test

المؤلفون: Mazhar Ajaz, Laurent Mortier, Inge Marie Svane, Ivan Marquez-Rodas, Thomas Eigentler, Jennifer Lord-Bessen, Paolo A. Ascierto, Elena Grigoryeva, Dirk Schadendorf, Caroline Robert, Linda Rollin, Jacopo Pigozzo, Nicolas Meyer, Michael Smylie, Rene Gonzalez, Alexander M. Menzies, Piotr Rutkowski, Céleste Lebbé, Abdel Saci

المصدر: Journal of Clinical Oncology
Lebbé, C, Meyer, N, Mortier, L, Marquez-Rodas, I, Robert, C, Rutkowski, P, Menzies, A M, Eigentler, T, Ascierto, P A, Smylie, M, Schadendorf, D, Ajaz, M, Svane, I M, Gonzalez, R, Rollin, L, Lord-Bessen, J, Saci, A, Grigoryeva, E & Pigozzo, J 2019, ' Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma : Results From the Phase IIIb/IV CheckMate 511 Trial ', Journal of Clinical Oncology, vol. 37, no. 11, pp. 867-875 . https://doi.org/10.1200/JCO.18.01998Test

مصطلحات موضوعية: 0301 basic medicine, Male, Cancer Research, Skin Neoplasms, Time Factors, Medizin, Gastroenterology, law.invention, 0302 clinical medicine, Antineoplastic Agents, Immunological, Randomized controlled trial, law, Skin Neoplasms/drug therapy, Antineoplastic Combined Chemotherapy Protocols, Clinical endpoint, Melanoma/drug therapy, Ipilimumab/administration & dosage, Melanoma, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Middle Aged, Progression-Free Survival, 3. Good health, Nivolumab/administration & dosage, Nivolumab, Oncology, 030220 oncology & carcinogenesis, Disease Progression, Female, Rapid Communication, medicine.drug, Adult, medicine.medical_specialty, Ipilimumab, Drug Administration Schedule, 03 medical and health sciences, Young Adult, Antineoplastic Agents, Immunological/administration & dosage, Double-Blind Method, Internal medicine, medicine, Humans, Dosing, Progression-free survival, Adverse effect, Aged, Neoplasm Staging, business.industry, Clinical trial, 030104 developmental biology, business

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7100d36b125a105d0de169d7144e1e3eTest
https://pubmed.ncbi.nlm.nih.gov/30811280Test